Literature DB >> 12491486

Breast cancer risk assessment models: applicability to African-American women.

Melissa L Bondy1, Lisa A Newman.   

Abstract

BACKGROUND: Mortality rates are higher among African-American women with breast cancer than they are among white women. This population subset can benefit from available risk reduction strategies. Optimal public health gains from chemoprevention strategies depend on the ability to assess accurately the risk for the individual. However, it is not known if existing breast cancer prediction models are accurate predictors of the disease among African-American women.
METHODS: Literature was reviewed for breast cancer risk prediction models and their validation studies. Reported data were also reviewed regarding the strength of established breast cancer risk factors for African-American women.
RESULTS: The two currently accepted breast cancer risk assessment models, the Gail Model and the Claus Model, were designed primarily to provide risk assessments for white women. Neither model has been validated in African-American women. Reported data are inconsistent regarding the prevalence and strength of risk factors included in these models.
CONCLUSIONS: Efforts should be made to validate existing risk assessment models in African-American women and future research should be directed at the identification of more reliable risk assessment features. Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11018

Entities:  

Mesh:

Year:  2003        PMID: 12491486     DOI: 10.1002/cncr.11018

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

Review 1.  Clinical genetic counselling for familial cancers requires reliable data on familial cancer risks and general action plans.

Authors:  K Hemminki; C Eng
Journal:  J Med Genet       Date:  2004-11       Impact factor: 6.318

2.  The Swedish family-cancer database: update, application to colorectal cancer and clinical relevance.

Authors:  Kari Hemminki; Charlotta Granström; Bowang Chen
Journal:  Hered Cancer Clin Pract       Date:  2005-01-15       Impact factor: 2.857

Review 3.  Should tamoxifen be used in breast cancer prevention?

Authors:  Rita Kramer; Powel Brown
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

4.  Assessing and managing breast cancer risk: clinical tools for advising patients.

Authors:  Bernard Friedenson
Journal:  MedGenMed       Date:  2004-01-14

5.  Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer.

Authors:  Wendie A Berg; Jeffrey D Blume; Jean B Cormack; Ellen B Mendelson; Daniel Lehrer; Marcela Böhm-Vélez; Etta D Pisano; Roberta A Jong; W Phil Evans; Marilyn J Morton; Mary C Mahoney; Linda Hovanessian Larsen; Richard G Barr; Dione M Farria; Helga S Marques; Karan Boparai
Journal:  JAMA       Date:  2008-05-14       Impact factor: 56.272

6.  How old are African American women when they receive their first mammogram? Results from a church-based study.

Authors:  Janice V Bowie; Anita M Wells; Hee-Soon Juon; Kim D Sydnor; Elisa M Rodriguez
Journal:  J Community Health       Date:  2008-08

7.  Breast cancer risk assessment in socioeconomically disadvantaged urban communities.

Authors:  Chyongchiou Jeng Lin; Bruce Block; Mary Patricia Nowalk; Mattie Woods; Edmund M Ricci; Keith H Morgenlander; Dwight E Heron
Journal:  J Natl Med Assoc       Date:  2007-07       Impact factor: 1.798

8.  American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.

Authors:  Kala Visvanathan; Rowan T Chlebowski; Patricia Hurley; Nananda F Col; Mary Ropka; Deborah Collyar; Monica Morrow; Carolyn Runowicz; Kathleen I Pritchard; Karen Hagerty; Banu Arun; Judy Garber; Victor G Vogel; James L Wade; Powel Brown; Jack Cuzick; Barnett S Kramer; Scott M Lippman
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

9.  A comparison of cancer risk assessment and testing outcomes in patients from underserved vs. tertiary care settings.

Authors:  Huma Q Rana; Sarah R Cochrane; Elaine Hiller; Ruth N Akindele; Callie M Nibecker; Ludmila A Svoboda; Angel M Cronin; Judy E Garber; Christopher S Lathan
Journal:  J Community Genet       Date:  2017-11-18

10.  Incorporating ethnicity into genetic risk assessment for Alzheimer disease: the REVEAL study experience.

Authors:  Kurt D Christensen; J Scott Roberts; Charmaine D M Royal; Grace-Ann Fasaye; Thomas Obisesan; L Adrienne Cupples; Peter J Whitehouse; Melissa Barber Butson; Erin Linnenbringer; Norman R Relkin; Lindsay Farrer; Robert Cook-Deegan; Robert C Green
Journal:  Genet Med       Date:  2008-03       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.